The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Safety and efficacy of venetoclax in combination with R-CHOP for patients with RT
In this video, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study evaluating the safety and efficacy of venetoclax in combination with R-CHOP for patients with Richter’s transformation (RT). A complete response (CR) rate of 50% and median progression-free survival (PFS) of 16 months have been observed. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
